107 related articles for article (PubMed ID: 31512028)
1. Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects.
Keyvanjah K; Cooke B; Martin D; Di Primeo D; Sterling L; Liang J; Olek E; Rubets I; Wong A
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1125-1132. PubMed ID: 31512028
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects.
Keyvanjah K; DiPrimeo D; Li A; Obaidi M; Swearingen D; Wong A
Br J Clin Pharmacol; 2017 Mar; 83(3):554-561. PubMed ID: 27628584
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
Br J Clin Pharmacol; 2011 Apr; 71(4):522-7. PubMed ID: 21395644
[TBL] [Abstract][Full Text] [Related]
4. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
Abbas R; Boni J; Sonnichsen D
Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
[TBL] [Abstract][Full Text] [Related]
5. Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole.
Kamali F; Huang ML
Br J Clin Pharmacol; 1996 Feb; 41(2):125-8. PubMed ID: 8838438
[TBL] [Abstract][Full Text] [Related]
6. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
7. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules).
Doser K; Meyer B; Nitsche V; Binkert-Graber P
Int J Clin Pharmacol Ther; 1995 Aug; 33(8):431-6. PubMed ID: 8556221
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
[TBL] [Abstract][Full Text] [Related]
11. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Abbas R; Leister C; Sonnichsen D
Clin Drug Investig; 2013 Aug; 33(8):589-95. PubMed ID: 23839484
[TBL] [Abstract][Full Text] [Related]
12. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
13. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
[TBL] [Abstract][Full Text] [Related]
14. Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study.
Hsyu PH; Pignataro DS; Matschke K
Clin Pharmacol Drug Dev; 2018 May; 7(4):373-381. PubMed ID: 29058816
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
Naing A; Kurzrock R; Adams LM; Kleha JF; Laubscher KH; Bonate PL; Weller S; Fitzgerald C; Xu Y; LoRusso PM
Invest New Drugs; 2012 Feb; 30(1):327-34. PubMed ID: 20842406
[TBL] [Abstract][Full Text] [Related]
16. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A; Wang-Smith L; Pham T; Laliberte K
J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
Cheng H; Leff JA; Amin R; Gertz BJ; De Smet M; Noonan N; Rogers JD; Malbecq W; Meisner D; Somers G
Pharm Res; 1996 Mar; 13(3):445-8. PubMed ID: 8692739
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
20. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
Gardin A; Gray C; Neelakantham S; Huth F; Davidson AM; Dumitras S; Legangneux E; Shakeri-Nejad K
Eur J Clin Pharmacol; 2018 Dec; 74(12):1593-1604. PubMed ID: 30105453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
